Cik细胞治疗对肺癌术后辅助化疗毒副反应的影响

The Cik cell treatment on lung cancer after neoadjuvant chemotherapy

目的:观察Cik细胞治疗对肺癌术后患者近期生活质量和化疗毒副作用的影响。方法:90例患者随机分为两组,对照组接受静脉全身化疗方案,实验组接受全身化疗联合Cik细胞治疗方案。观察第2周期化疗前患者生活质量评分(quality of life,QOL)变化情况及第2周期化疗期间血液学毒副反应、消化系统不良反应、外周血淋巴细胞和淋巴因子变化。结果:全身化疗联合Cik细胞治疗组患者的QOL均值(92±3.4)高于全身化疗组(85±5.5),差异具有统计学意义(P<0.05);全身化疗联合Cik细胞治疗组患者血小板减少、白细胞下降的发生率要低于全身化疗组(P<0.05),差异具有统计学意义。两组在胃肠道反应发生率方面无统计学差异(P>0.05)。全身化疗联合Cik细胞治疗组患者的CD3+、CD4+/CD8+、IFN-γ和IL-2的均值较全身化疗组高,差异具有统计学意义(P<0.05)。结论:对肺癌术后进行全身化疗的患者,联合Cik细胞治疗能提高肺癌术后患者的近期生活质量,减轻术后化疗过程中的骨髓抑制,有增强和调节化疗期间患者免疫功能的作用。消化系统不良反应的发生率与全身化疗无差异,是一种较为理想的治疗方案。

Objective：To observe the effec of Cik cell therapy on postoperative lung cancer patients and chemo- theral^y side effects. Methods： All 90 patients were randomly divided into two groups, control group received intrave- nous systemic chemotherapy, the experimental group received systemic chemotherapy combined the Cik cell therapy. Results：The systemic chemotherapy patients QOL mean joint the Cik cell therapy group （92 ~ 3.4） was higher than the systemic chemotherapy group （ 85 ~ 5.5 ）, （ P 〈 0.05 ） ; joint the Cik cell treatment in patients with systemic chemotherapy thrombocytopenia leukopenia and the incidence was lower than the systemic chemotherapy group （ P 〈 0.05）. No significant difference between the two groups in the incidence of gastrointestinal reactions （ P 〉 0.05 ）. Pa- tients with systemic chemotherapy and the Cik cell therapy group CD3, CIM＇s/CD8 of IFN -/and IL- 2 mean was higher than systemic chemotherapy group, a statistically significant difference （ P 〈 0.05 ）. Conclusion： The systemic chemotherapy in patients with lung cancer after surgery,joint the Cik cell therapy can improve patients quality of life, reduce postoperative hone marrow suppression, enhance immune function in patients during chemotherapy. There is no difference in the incidence of adverse reactions associated with systemic chemotherapy.